Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 trial of TER-2013 in solid tumors with AKT/PI3K/PTEN pathway alterations
2025-525036-34-00Phase 2Authorised
- Sponsor
- Terremoto Biosciences Inc.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of TER-2013 in Nonhematologic neoplasms, ovarian cancer, Cervical Cancer (CC) and 5 more (4 arms), sponsored by Terremoto Biosciences Inc. Primary endpoints: Safety and tolerability, Dose-limiting toxicities and 5 more. Planned start Sep 2026; status: authorised.
02
Drugs
TER-2013
03
Conditions
Nonhematologic neoplasmsovarian cancerCervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)bronchial carcinoma
Beyond the preview
Go deeper on 2025-525036-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525036-34-00.